JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports
Dermatology Research and Practice · 2026-01 · 2026 (1)
DOI: 10.1155/drp/7086209 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Dermatology Research and Practice, online erschienen am 18.07.2026. Verfasst von Seyed Mohammad Vahabi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neutrophilic dermatoses, including pyoderma gangrenosum (PG) and Sweet syndrome (SS), are inflammatory disorders characterized by neutrophilic infiltration without infection. Conventional therapies are often inadequate. We aim to evaluate the efficacy and safety of JAK inhibitors (JAK‐I) in the treatment of PG and SS. The study was registered (PROSPERO‐CRD420251113331), and a relevant search was conducted on PubMed/MEDLINE, Scopus, Web of Science, and Embase until July 27, 2025. Included studies were English language reports describing PG or SS treated with any JAK‐I or cases of JAK‐I–associated SS. Reviews, animal studies, and reports with insufficient clinical data were excluded. Four reviewers independently screened records. Data extraction included demographics, comorbidities, treatment regimens, outcomes, and adverse events. Risk of bias was assessed using the National Heart, Lung, and Blood Institute and Murad et al. tools through discussion‐based consensus. Due to heterogeneous outcome definitions and small sample sizes, only descriptive synthesis was performed. Fifty‐four reports, including 70 patients (59 PG, 5 SS) treated with JAK‐I and 6 JAK‐I–associated SS, were included. Across 43 PG studies, five JAK‐Is—tofacitinib, upadacitinib, baricitinib, abrocitinib, and ruxolitinib—produced 33 complete and 26 partial responses. Twenty‐six patients (44.1%) received monotherapy. Most patients (51/59; 86.4%) had at least one comorbidity. Adverse events occurred in 6 (10.1%), including anemia, hypertension, renal dysfunction, fatigue, and acneiform eruption. Among 11 SS reports, all 5 treated patients achieved complete resolution with baricitinib, ruxolitinib, or filgotinib. Six additional cases described ruxolitinib‐associated SS, generally improving with corticosteroids or drug withdrawal. Most studies were rated good quality. Evidence is limited to small cases with heterogeneous outcome definitions, variable dosing, and inconsistent follow‐up. JAK‐Is are associated with clinical improvement in PG and selected SS cases and may serve as useful adjunct therapies, though caution is needed in patients with hematologic malignancies. Larger controlled studies are needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
- Autoimmune Bullous Diseases Research Center, Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
ORCID-Profile: Seyed Mohammad Vahabi, Sama Heidari, Yalda Farahmand, Elnaz Pourgholi, Nika Kianfar, Huria Memari, Farzad Esmaeili, Saeed Bahramian, Ifa Etesami, Mahshid Sadat Ansari
Zitieren
APA
Vahabi, S. M., Heidari, S., Farahmand, Y., Pourgholi, E., Kianfar, N., Memari, H., Esmaeili, F., Bahramian, S., Etesami, I., & Ansari, M. S. (2026). JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports. Dermatology Research and Practice, 2026(1). https://doi.org/10.1155/drp/7086209
Vancouver
Vahabi SM, Heidari S, Farahmand Y, Pourgholi E, Kianfar N, Memari H, et al. JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports. Dermatology Research and Practice. 2026;2026(1). doi:10.1155/drp/7086209
BibTeX
@article{Vahabi2026,
author = {Vahabi, Seyed Mohammad and Heidari, Sama and Farahmand, Yalda and Pourgholi, Elnaz and Kianfar, Nika and Memari, Huria and Esmaeili, Farzad and Bahramian, Saeed and Etesami, Ifa and Ansari, Mahshid Sadat},
title = {JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports},
journal = {Dermatology Research and Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/drp/7086209}
}
EUVIMED